Skip to main content

Table 2 Documents required for DEEP-2 submission compared to the EC Guidance [5, 6]1

From: Ethical and procedural issues for applying researcher-driven multi-national paediatric clinical trials in and outside the European Union: the challenging experience of the DEEP project

Documents required by the EC Guidance

 

EU

Non-EU

CY

GR

IT2

UK

AL

EG

TU

For EC approval

Cover letter, protocol, CTA form, information on countries and sites involved, synopsis in the national language, I.B./SmPC, insurance

x

x

x

x

x

x

x

Receipt of confirmation of EudraCT number, agreement between sponsor and site

x

x

x

x

   

List of involved Competent Authorities

x

x

x5

x

   

PIP opinion/link to the specific documentation4

 

x

x5

x

   

IMPD, NIMPD (including GMP compliance)

 

x

x5

x

x

x

x

Examples of the label in the national language

 

x

x5;6

x

x

x

x

Outline of all active trials with the same IMP

  

x3

    

Information documents for parents/legal representative, consent form, any other material used for the recruitment

x

x

x

x

x

x

x

Information material for children, assent form

  

x

x

 

x

 

CVs of Investigators, Investigator disclosure of conflict of interest

x

x

x

x

x

x

 

Quality of facilities for the trial

x

x

x

  

x

 

For CA authorisation

Cover letter, protocol, CTA form, contents of the labelling, I.B. /SmPC

x

x

x3

x

x

x

x

IMPD, NIMPD (including GMP compliance)

x

x

x

x

x

 

x

Insurance

x

x

x

 

x

x

x

EC opinion (where available)

 

x

x

x

 

x

x

PIP opinion/link

 

x

x

x

   

Proof of payment

x

x

n.a

x

 

x

 

Agreement between sponsor and site

  

x

   

x

  1. n.a.: not applicable for DEEP-2 trial given the non-profit nature of the trial; IMPD: Investigational Medicinal Product Dossier; NIMPD: Not-Investigational Medicinal Product Dossier
  2. 1Scientific Advice, Indemnity/compensation for participants and rewards to investigators, unjustified/unexpected impurities, viral safety information, GMOs, radiopharmaceuticals, TSE certificate required by EC Guidance on ECs submission [5] not foreseen in DEEP-2 trial. Scientific Advice, Indemnity/compensation for participants and rewards to investigators required by EC Guidance on CAs submission [6] not foreseen in DEEP-2 trial
  3. 212 CAs addressed in Italy
  4. 3, 62 out of 12 sites in Italy
  5. 4 The PIP not mentioned in the Guidance [5], being issued after the Paediatric Regulation [17], but required by the EC
  6. 5 Only the EC issuing the single opinion